ArticleFrontiers in oncology2022

Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study.

Jingjing Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.